Establishing Normative Baselines for Precision Pathology

You are reading version 1 of this direction, frozen 2026-10-04. The latest version is version 2.

Version 1 of 2130 papers132 conceptsfrozen 2026-10-04

To understand why a machine is broken, you first need to know how it works when it is functioning perfectly. In clinical research, however, we often skip this step. We study the "broken" state—the disease—by comparing it to other "slightly less broken" states, such as benign tumors or patients with different pathologies.

A growing body of research argues that this lack of a true normative baseline is a fundamental bottleneck in medicine. Without a high-resolution map of the "healthy" state, we cannot distinguish between a specific disease driver and a general marker of inflammation, aging, or stress.

The Problem of Pathological Controls

In many clinical studies, researchers use "control groups" that are not actually healthy. For instance, Chaojie Yu and Jiali Chen have noted that using pathological tissues as a control group can obscure the baseline molecular state. If you compare a severely inflamed joint to a mildly degraded one, you might find markers of "severe inflammation," but you miss the fundamental shift from "healthy" to "diseased."

This issue extends to diagnostics. Lu Wang found that while comparing endometriosis patients to those with other gynecological conditions helps differentiate diseases, it fails to establish a baseline against a completely healthy population. This makes it difficult to see the full extent of physiological deviation. Similarly, Weicong Xu argues that using patients with benign conditions as controls risks masking subtle but significant microbial signatures that would only be visible against a truly healthy baseline.

Why We Lack Healthy Data

If healthy controls are so important, why are they often missing? The answer is usually ethical or logistical.

  1. Invasive Procedures: It is ethically difficult to perform a bronchoscopy on a healthy child to map their lung microbiome, as noted in Differences in pulmonary microbiota of severe community-acquired pneumonia.
  2. Clinical Access: Researchers often collect samples during necessary surgeries. This is why Xueli Zhang points out that biliary health baselines are constrained; you only get bile samples from people who already have a reason to be in the operating room.
  3. The "Average" Trap: Even when we have data from "unselected" populations, Arinbjörn Kolbeinsson explains that mixing healthy and diseased individuals makes it impossible to define a clear trajectory for normal aging.

Building the Gold Standard Map

To solve this, researchers are shifting toward creating "Gold Standard" reference maps of healthy human biology. Caitríona M. McEvoy recently profiled over 27,000 cells from living kidney donors to create a steady-state template. This map revealed sex-based metabolic differences that would be invisible in a diseased population where pathology overrides normal physiology.

In the gut, Themistoklis Kourkoumpetis mapped the "mycobiome" of healthy colons, discovering that certain fungi like Malassezia are normal residents, not just invaders. Without this baseline, a clinician seeing Malassezia in a sick patient might mistakenly label it a pathogen.

Impact on Machine Learning and Causal Discovery

The absence of a baseline doesn't just hurt biological intuition; it cripples our predictive models. Saurabh Kataria 0001 found that evaluating cardiac arrest models against "recovering" patients rather than healthy ones can inflate performance metrics by providing "easy" negatives.

Furthermore, David C. Miller argues that clinical datasets containing only diseased samples lack the necessary variance for causal discovery. Without healthy controls, a statistical model might identify a "causal driver" that is actually just a common symptom shared by everyone in the sick cohort.

By prioritizing the "healthy state" as a research object in its own right, the field is moving toward a more precise definition of what it means for a biological system to go wrong. As Bing He suggests with the ASGARD pipeline, the future of drug repurposing and personalized medicine depends on our ability to measure exactly how far a single cell has strayed from its normal, healthy path.

Papers in this version

Showing 60 of 130 papers.

History & citationVersion 2 · 2026-10-04

Current · Permanent link

  1. Version 2 (latest) · 2026-10-04 · 135 papers
  2. Version 1 · 2026-10-04 · 130 papers
Cite this direction

Latest version (a living page):

@misc{lacuna_control_group_absence_df25466e,
  title = {control group absence},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/control-group-absence/rdr_df25466e5df9445dad9b01e01741c071},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-20},
}

This exact version (version 1, frozen text):

@misc{lacuna_establishing_normative_baselines_for_pre_df25466e_v1,
  title = {Establishing Normative Baselines for Precision Pathology},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/establishing-normative-baselines-for-precision-pathology/rdr_df25466e5df9445dad9b01e01741c071/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-20},
}